Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com

Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

By Rose McNulty

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center

ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

By Mary Caffrey

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com

5 Key FDA Approval Dates Mark a Milestone-Filled May

By Brooke McCormick

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

December 17th 2015

Need to Lower Drug Costs, Not the Size of the Donut Hole, for Medicare Beneficiaries With Cancer

Surabhi Dangi-Garimella, PhD

A study in the Journal of Clinical Oncology predicts financial stress on Medicare Part D beneficiaries on oral anticancer medicines, even after the expected closing of the donut hole in 2020.

December 16th 2015

Kadcyla and Opdivo Too Expensive for NICE

AJMC Staff

NICE rejects promising oncology agents once again, citing high drug cost.

December 16th 2015

FDA Updates: Oncology

Surabhi Dangi-Garimella, PhD

Several new FDA approvals and research advances in oncology have the potential for improved outcomes among cancer patients.

December 16th 2015

Managed Care Updates: Oncology

Surabhi Dangi-Garimella, PhD

Updates on screening age recommendations for mammograms, CDC report on a decline in smoking rates in the country, and regulation of laboratory-developed tests.

December 15th 2015

Dr Michael Kolodziej Outlines Ways to Reform 340B

There are 3 potential solutions for reforming the 340B drug pricing program, according to Michael Kolodziej, MD, national medical director of oncology solutions in the Office of the Chief Medical Officer at Aetna.

December 15th 2015

Choosing Wisely: Eliminating Unnecessary Biopsies

Surabhi Dangi-Garimella, PhD

A retrospective analysis of phase 1 oncology studies that used biopsy-derived pharmacodynamic biomarkers, could not draw a correlation between subsequent drug development and biopsy sample collection.

December 15th 2015

The Struggle Between Oncology Care Cost and Value

Joseph Alvarnas, MD

While cost is an important component of value, it tells only a small part of the cancer care story. By focusing on issues of payment and cost alone, we miss our opportunity to engage cancer care stakeholders in the process of creating a more effective system of care.

December 15th 2015

Patient Access to Oncology Care in ACA Exchange Plans

Caroline F. Pearson Deirdre B. Parsons, MPP, MPH, MS

This article describes provider networks and benefit design-including deductibles, cost-sharing, and maximum out-of-pocket limits-for oncology care in 2015 health insurance exchanges.

December 15th 2015

Healthcare Leaders Offer Solutions for Reforming 340B in New Issue of Evidence-Based Oncology

Depending on one's point of view, the 340B prescription drug program keeps safety net hospitals afloat or serves as a profit center at the expensive of community providers. Three leading voices-Rena M. Conti, PhD; Peter B. Bach, MD, MAPP; and Michael Kolodziej, MD; recommend reforms in the new issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care.

December 15th 2015

PrecisionFDA Launched With Promise of Transparency and Quality Care

Surabhi Dangi-Garimella, PhD

The FDA, today, launched precisionFDA, a cloud-based platform that members can utilize to access and share data sets, analysis pipelines, and bioinformatics tools.

December 15th 2015

ACCC ICLIO meeting

Surabhi Dangi-Garimella, PhD

At the first annual conference of the Institute for Clinical Immuno-Oncology on October 1, 2015, in Philadelphia, the discussion revolved around integrating immuno-oncology into clinical practice and programs that assist with patient access to these treatments.

December 15th 2015

COA Payer Summit

Surabhi Dangi-Garimella, PhD

Providers and payers came together to discuss challenges and share success stories as they adapt to the changing healthcare realm.

December 14th 2015

Measuring Financial Toxicity in Cancer Patients

Pauline Lee, PharmD Jonas A. de Souza, MD

With the rising costs of cancer care, evidence-based tools can help physicians screen patients for financial toxicity.

December 14th 2015

Eliminating a Barrier to Cancer Care through Universal Fair Access to Oral Chemotherapy Medications

Christopher Hansen

The advocacy affiliate of the American Cancer Society, the American Cancer Society Cancer Action Network, is working across the country to pass and implement strong oral chemotherapy fairness laws to help ensure cancer patients have access to the recommended course of treatment without added out-of-pocket costs based on how their drug is administered.

December 14th 2015

The Financial Impact of Cancer Care: Implications and Potential Solutions

Veena Shankaran, MD, MS

Addressing the financial burden of cancer treatment requires efforts at the policy, payer, and clinic level, and implementation of these strategies, in clinical practice, requires commitment from various stakeholders.

December 14th 2015

Impact of Oral Parity: A Personal Story

Christopher Hansen

Oral chemotherapy ensured improved quality of life for a young, stage 3 pancreatic cancer patient.

December 14th 2015

Healthcare Transparency in Need of Academic Vigilance

Surabhi Dangi-Garimella, PhD

A report by STAT has found that a majority of institutions conducting clinical trials fail to report their results to the website ClinicalTrials.gov.

December 14th 2015

What We Need to Know About Bladder Cancer and Its Treatment

AJMC Staff

There is, currently, an unmet need in bladder cancer, a disease expected to be responsible for 16,000 deaths in 2015.

December 14th 2015

What We're Reading: Public Health Initiatives Are Underfunded in the US

AJMC Staff

What we're reading, December 14, 2015: public health initiatives are underfunded despite being a big return on investment; the FDA repeatedly approved the cancer drug Afinitor without proof it extended life; and a nurse may have exposed patients in a maternity wing to tuberculosis.

December 13th 2015

Dr Stacey W. McCullough Discusses High-Cost Therapies and Me-Too Drugs

Stacey W. McCullough, PharmD, senior vice president of pharmacy at Tennessee Oncology, discussed strategies for managing high-cost treatments, the impact of me-too drugs, and how clinical pathways can help physicians make treatment decisions at the point of care.

December 12th 2015

This Week in Managed Care: December 12, 2015

This week in managed care, an analysis found the penalty for being uninsured will exceed the cost of insurance for most Americans in 2016, thousands met for the annual meeting of the American Society of Hematology, and Horizon Blue Cross Blue Shield's OMNIA plan gets good news and bad news in New Jersey.

December 11th 2015

Alectinib for ALK-Positive NSCLC Approved

Surabhi Dangi-Garimella, PhD

Within 3 months of being granted priority review, alectinib (Alecensa) has been approved for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed or who cannot tolerate crizotinib

December 11th 2015

NCCS Responds to CMS, Demands Flexibility With Alternative Payment Models

Surabhi Dangi-Garimella, PhD

The National Coalition for Cancer Survivorship has submitted comments to CMS, providing feedback on the Merit-Based Incentive Payment System and Alternative Payment Models proposed by CMS as it transitions toward value-based reimbursement.

December 11th 2015

Dr Yousuf Zafar Explains Interventions to Combat Rising Drug Prices

When considering how to rectify the rising prices of drugs, there are a number of interventions at multiple levels that can work to decrease costs to patients and the price of the drug, explained Yousuf Zafar, MD, MHS, associate professor in the Division of Medical Oncology at Duke Cancer Institute.

December 11th 2015

Is There a Mathematical Resolution to the Cost-Versus-Value Debate?

Bruce Feinberg, DO Lincy S. Lal, PharmD, PhD J. Michael Swint, PhD

Solutions proposed by patient advocates and physicians to control costs provide approaches to valuing new drug/treatments compared with 1 or several prevailing standards of care. Increasingly, however, the debate over cost is transitioning to a debate over value.

December 11th 2015

Managing Costs and Enhancing the Value of Oncology Care

Surya Singh, MD Christine Sawicki, RPh, MBA Ken Vander Pyl Alan Lotvin, MD

Management of high and rising costs in oncology requires a multifaceted approach using both innovative strategies and pragmatic tools. In this article, we discuss several factors that influence the costs of oncology care.

December 11th 2015

Maximizing Value of Freestanding and Outpatient Hospital Setting in Cancer Care Delivery

Constantine Mantz, MD

A unique collaboration between 21st Century Oncology and Lee Memorial Hospital showed marked improvements in efficiencies, care, and patient experience.

December 10th 2015

Health IT-Assisted Population-Based Preventive Cancer Screening: A Cost Analysis

Douglas E. Levy, PhD Vidit N. Munshi, MA Jeffrey M. Ashburner, PhD, MPH Adrian H. Zai, MD, PhD, MPH Richard W. Grant, MD, MPH Steven J. Atlas, MD, MPH

An automated cancer screening outreach tool implemented in a mature health information technology environment can achieve cost savings through reduced clinician time devoted to screening efforts.

December 10th 2015

What We're Reading: 1 Million New Sign-Ups for ACA Insurance

AJMC Staff

What we're reading, December 10, 2015: the Affordable Care Act has signed up 1 million new enrollees; Medicare patients spend more on oral cancer drugs than food each year; and the CDC found life expectancy remains at 79 years for the third year in a row.

December 10th 2015

Partial Mastectomy Findings at Yale Could Add Value for Patient and Payer

Surabhi Dangi-Garimella, PhD

Research conducted at the Yale Cancer Center has found that a procedure known as cavity shave margins could avoid unnecessary follow-up surgeries and save time and costs.

...

114 115 116 117 118 119 120 121 122

...

185 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions